icon-    folder.gif   Conference Reports for NATAP  
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
Single Doses as Low as 0.5 mg of the Novel NRTTI
MK-8591 Suppress HIV for At Least Seven Days

  Reported by Jules Levin
9th IAS Conference on HIV Science; Paris, France; 23-26 July 2017
Randolph P Matthews1; Dirk Schurmann2; Deanne Jackson Rudd1; Vanessa Levine1; Sabrina Fox-Bosetti1; Sandra Zhang1; Martine Robberechts1; Inge De Lepeleire1; Andreas Huser2; Daria J Hazuda1; Marian Iwamoto1; and Jay A Grobler1 on behalf of the HIV Early Development Team 1Merck & Co., Inc., Kenilworth, NJ, USA; 2Charite Research Organisation, Berlin, Germany
IAS: Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)
CROI: Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16)
CROI: A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16)